Using probiotics to reduce the harmful effects of environmental toxins
Official title: Novel probiotics to mitigate xenobiotic toxicity through microbial biotransformation
Funded at Nexilico, INC. · NIH-10707553 · Data updated 2026-11-12
This study is looking at how certain friendly bacteria, or probiotics, can help your body deal with harmful chemicals from the environment, making it easier for you to stay healthy.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Nexilico, INC. NIH-funded |
| Lab location | 1 site (Danville, UNITED STATES) |
| Project start | September 1, 2023 |
| Project end | August 31, 2025 |
| Funding year | 2023 |
| Award (this year) | $275,765 |
| NIH project number | 1R41ES034979-01A1 |
| Project ID | NIH-10707553 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research include individuals exposed to environmental toxins or those with conditions related to xenobiotic toxicity.
✕Less likely to help
Patients who are not exposed to environmental toxins or have no related health conditions may not benefit from this research.
What this research studies
This research investigates how certain probiotics can help reduce the toxicity of harmful environmental chemicals in the human body. By studying the gut microbiome, which consists of trillions of microorganisms, the research aims to identify specific strains that can transform these toxins into less harmful substances. The approach combines advanced computational techniques with laboratory experiments to test various microbial enzymes and their effects on toxicity. Patients may benefit from improved health outcomes by utilizing these probiotics to mitigate the effects of toxic exposures.
Why it matters
Potential benefit: If successful, this research could lead to new probiotic treatments that protect patients from the harmful effects of environmental toxins.
How similar studies have gone: Previous research has shown promise in using probiotics to modulate toxicity, but this specific approach to identifying protective microbial strains is relatively novel.
Where this research is happening
-
Nexilico, INC.
Danville, United States Active
Researchers
- Principal investigator: Soheilypour, Mohammad — Nexilico, INC.
- Study coordinator: Soheilypour, Mohammad
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.